16867021|t|Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
16867021|a|Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia. The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively. (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy. Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05). However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.). RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters. On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05). Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.). Climbing behavior induced by apomorphine was reduced in animals treated with THP. Such an effect was, however, reversed in presence of RAMH. THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia.
16867021	0	13	Antipsychotic	ChemicalEntity	D014150
16867021	30	42	thioperamide	ChemicalEntity	C052075
16867021	56	67	H3-receptor	GeneOrGeneProduct	99296
16867021	82	86	mice	OrganismTaxon	10090
16867021	195	208	schizophrenia	DiseaseOrPhenotypicFeature	D012559
16867021	264	287	histamine H(3)-receptor	GeneOrGeneProduct	99296
16867021	299	310	neuroleptic	ChemicalEntity	D014150
16867021	319	328	catalepsy	DiseaseOrPhenotypicFeature	D002375
16867021	330	341	apomorphine	ChemicalEntity	D001058
16867021	372	383	amphetamine	ChemicalEntity	D000661
16867021	416	420	mice	OrganismTaxon	10090
16867021	422	431	Catalepsy	DiseaseOrPhenotypicFeature	D002375
16867021	447	458	haloperidol	ChemicalEntity	D006220
16867021	481	492	apomorphine	ChemicalEntity	D001058
16867021	514	525	amphetamine	ChemicalEntity	D000661
16867021	622	647	(R)-alpha-methylhistamine	ChemicalEntity	C069357
16867021	649	653	RAMH	ChemicalEntity	C069357
16867021	677	689	thioperamide	ChemicalEntity	C052075
16867021	691	694	THP	ChemicalEntity	C052075
16867021	734	743	catalepsy	DiseaseOrPhenotypicFeature	D002375
16867021	763	766	THP	ChemicalEntity	C052075
16867021	810	821	haloperidol	ChemicalEntity	D006220
16867021	867	876	catalepsy	DiseaseOrPhenotypicFeature	D002375
16867021	922	926	RAMH	ChemicalEntity	C069357
16867021	968	971	THP	ChemicalEntity	C052075
16867021	989	993	RAMH	ChemicalEntity	C069357
16867021	1089	1092	THP	ChemicalEntity	C052075
16867021	1154	1165	amphetamine	ChemicalEntity	D000661
16867021	1174	1187	hyperactivity	DiseaseOrPhenotypicFeature	D006948
16867021	1189	1192	THP	ChemicalEntity	C052075
16867021	1309	1313	RAMH	ChemicalEntity	C069357
16867021	1372	1375	THP	ChemicalEntity	C052075
16867021	1424	1435	apomorphine	ChemicalEntity	D001058
16867021	1472	1475	THP	ChemicalEntity	C052075
16867021	1530	1534	RAMH	ChemicalEntity	C069357
16867021	1536	1539	THP	ChemicalEntity	C052075
16867021	1553	1566	antipsychotic	ChemicalEntity	D014150
16867021	1596	1607	haloperidol	ChemicalEntity	D006220
16867021	1616	1625	catalepsy	DiseaseOrPhenotypicFeature	D002375
16867021	1636	1647	amphetamine	ChemicalEntity	D000661
16867021	1656	1669	hyperactivity	DiseaseOrPhenotypicFeature	D006948
16867021	1683	1694	apomorphine	ChemicalEntity	D001058
16867021	1715	1719	mice	OrganismTaxon	10090
16867021	1737	1740	THP	ChemicalEntity	C052075
16867021	1758	1762	RAMH	ChemicalEntity	C069357
16867021	1793	1817	histamine H(3)-receptors	GeneOrGeneProduct	99296
16867021	1852	1877	H(3)-receptor antagonists	ChemicalEntity	D054828
16867021	1915	1928	schizophrenia	DiseaseOrPhenotypicFeature	D012559
16867021	Negative_Correlation	D054828	D012559	Novel
16867021	Positive_Correlation	D014150	D002375	No
16867021	Positive_Correlation	D006220	D002375	No
16867021	Positive_Correlation	D000661	D006948	No
16867021	Negative_Correlation	C069357	C052075	Novel
16867021	Association	C069357	99296	Novel
16867021	Negative_Correlation	C052075	D001058	Novel
16867021	Positive_Correlation	C052075	D002375	Novel
16867021	Positive_Correlation	C052075	D006220	Novel
16867021	Negative_Correlation	C052075	D006948	Novel
16867021	Negative_Correlation	C052075	D000661	Novel
16867021	Negative_Correlation	99296	C052075	Novel